Keppra 100 mg/ml oral solution
Spain
Table of Contents
Package Leaflet: Information for the User
Introduction
Package leaflet: information for the patient
Keppra 100 mg/ml oral solution
Levetiracetam
Read the entire leaflet carefully before you or your child starts taking this medicine, because it contains important information for you.
- Keep this leaflet as you may need to read it again.
- If you have any questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, because it could harm them.
- If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.
Leaflet Contents
- What Keppra is and what it is used for
- What you need to know before taking Keppra
- How to take Keppra
- Possible adverse effects
- How to store Keppra
- Contents of the pack and other information
1. What Keppra is and what it is used for
Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).
Keppra is used:
- as monotherapy in adults and adolescents 16 years of age or older with newly diagnosed epilepsy to treat a type of epilepsy. Epilepsy is a condition in which patients have seizures. Levetiracetam is used for the type of epilepsy in which seizures initially affect only one side of the brain but may then spread to broader areas on both sides of the brain (partial-onset seizures with or without secondary generalization). Your doctor has prescribed levetiracetam to reduce the number of seizures.
- in combination with other antiepileptic medicines to treat:
- partial-onset seizures with or without secondary generalization in adults, adolescents, children, and infants from 1 month of age.
- myoclonic seizures (brief, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.
- primary generalized tonic-clonic seizures (grand mal seizures, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalized epilepsy (a type of epilepsy thought to have a genetic cause).
2. What you need to know before taking Keppra
Do not take Keppra
If you are allergic to levetiracetam, to pyrrolidone derivatives, or to any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor before starting Keppra
If you have kidney problems, follow your doctor's instructions, as they will decide whether your dose needs to be adjusted.
If you notice any growth delay in your child or unexpected development of puberty, contact your doctor.
A small number of people taking antiepileptic medicines such as Keppra have had thoughts of harming themselves or of suicide. If you experience any symptoms of depression and/or suicidal thoughts, contact your doctor.
If you have a personal or family history of irregular heartbeat (visible on electrocardiogram), or if you have a disease and/or are taking treatment(s) that may make you prone to cardiac arrhythmias or electrolyte imbalances.
Inform your doctor or pharmacist if any of the following side effects worsen or last longer than a few days:
Abnormal thoughts, feeling irritable, or reacting more aggressively than usual, or if you or your family and friends notice significant changes in mood or behaviour.
Worsening of epilepsy:
Rarely, epileptic seizures may worsen or occur more frequently, especially during the first month after starting treatment or increasing the dose.
In a very rare form of early-onset epilepsy (epilepsy associated with SCN8A mutations) causing multiple seizure types and loss of skills, you may notice that seizures persist or worsen during treatment.
If you experience any of these new symptoms while taking Keppra, seek medical advice as soon as possible.
Children and adolescents
Treatment with Keppra alone (monotherapy) is not indicated in children and adolescents under 16 years of age.
Taking Keppra with other medicines
Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.
Do not take macrogol (a medicine used as a laxative) within one hour before or one hour after taking levetiracetam, as it could reduce its effectiveness.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before using this medicine. Levetiracetam may only be used during pregnancy if, after careful evaluation, your doctor considers it necessary.
Do not stop your treatment without first discussing it with your doctor.
The risk of birth defects in the baby cannot be completely ruled out. Two studies do not suggest an increased risk of autism or intellectual disability in children born to mothers treated with levetiracetam during pregnancy. However, available data on the impact of levetiracetam on infant neurological development are limited.
Breastfeeding is not recommended during treatment.
Driving and using machines
Keppra may affect your ability to drive or operate tools or machinery, as it may cause drowsiness. This is more likely at the beginning of treatment or when the dose is increased. You should not drive or use machinery until you are certain that your ability to perform these activities is not impaired.
Keppra contains methyl parahydroxybenzoate, propyl parahydroxybenzoate, and maltitol
Keppra 100 mg/ml oral solution, due to the presence of methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216), may cause allergic reactions (possibly delayed).
Keppra oral solution also contains maltitol. If your doctor has informed you that you have an intolerance to certain sugars, contact your doctor before taking this medicine.
Keppra contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per ml; hence, it is essentially "sodium-free".
3. How to take Keppra
Follow exactly the instructions for using this medicine as given by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
Keppra should be taken twice daily, once in the morning and once in the evening, approximately at the same time each day.
Take the oral solution as directed by your doctor.
Monotherapy (from 16 years of age)
Adults (≥18 years) and adolescents (from 16 years of age):
For patients from 4 years of age, measure the appropriate dose using the 10 ml syringe provided in the package.
Recommended dose: Keppra is taken twice daily, in two equal doses, with each individual dose ranging from 5 ml (500 mg) to 15 ml (1,500 mg).
When you start taking Keppra, your doctor will prescribe a lower dose for two weeks before administering the lowest daily dose.
Concomitant therapy
Dosing in adults and adolescents (12 to 17 years of age):
For patients from 4 years of age, measure the appropriate dose using the 10 ml syringe provided in the package.
Recommended dose: Keppra is taken twice daily, in two equal doses, with each individual dose ranging from 5 ml (500 mg) to 15 ml (1,500 mg).
Dosing in children from 6 months of age:
Your doctor will prescribe the most appropriate pharmaceutical form of Keppra depending on the child's age, weight, and required dose.
For children from 6 months to 4 years of age, measure the appropriate dose using the 5 ml syringe provided in the package.
For children over 4 years of age, measure the appropriate dose using the 10 ml syringe provided in the package.
Recommended dose: Keppra is taken twice daily, in two equal doses, with each individual dose ranging from 0.1 ml (10 mg) to 0.3 ml (30 mg) per kg of the child's body weight (see examples of dosing in the table below).
Dosing in children from 6 months of age:
Weight | Initial dose: 0.1 ml/kg twice daily | Maximum dose: 0.3 ml/kg twice daily |
6 kg | 0.6 ml twice daily | 1.8 ml twice daily |
8 kg | 0.8 ml twice daily | 2.4 ml twice daily |
10 kg | 1 ml twice daily | 3 ml twice daily |
15 kg | 1.5 ml twice daily | 4.5 ml twice daily |
20 kg | 2 ml twice daily | 6 ml twice daily |
25 kg | 2.5 ml twice daily | 7.5 ml twice daily |
From 50 kg | 5 ml twice daily | 15 ml twice daily |
Dosage in infants (from 1 month to less than 6 months):
For infants from 1 month to less than 6 months of age, measure the appropriate dose using the 1 ml syringe provided in the package.
Recommended dose: Keppra is taken twice daily, in two equal doses, with each individual dose ranging from 0.07 ml (7 mg) to 0.21 ml (21 mg) per kg of the infant's body weight (see the following table for dose examples).
Dosing in infants (from 1 month to less than 6 months of age):
Weight | Initial dose: 0.07 ml/kg twice daily | Maximum dose: 0.21 ml/kg twice daily |
4 kg | 0.3 ml twice daily | 0.85 ml twice daily |
5 kg | 0.35 ml twice daily | 1.05 ml twice daily |
6 kg | 0.45 ml twice daily | 1.25 ml twice daily |
7 kg | 0.5 ml twice daily | 1.5 ml twice daily |
Administration method:
After measuring the correct dose with the appropriate syringe, Keppra oral solution may be diluted in a glass of water or in a feeding bottle. Keppra may be taken with or without food. After oral administration of levetiracetam, a bitter taste may be noticed.
Instructions on how to use the syringe:
- Open the bottle: press down on the cap and unscrew it counterclockwise (figure 1)
-
Follow these steps the first time you take Keppra:
-
Separate the oral dosing adapter from the oral syringe (figure 2).
-
Place the adapter onto the top of the bottle (figure 3). Make sure it is securely fixed in place. It is not necessary to remove the adapter after use.
-
Follow these steps every time you take Keppra:
-
Attach the oral syringe to the opening of the adapter (figure 4).
-
Turn the bottle upside down (figure 5).
-
Hold the bottle upside down with one hand and use the other hand to fill the oral syringe.
-
Pull the plunger down to fill the oral syringe with a small amount of solution (figure 5A).
-
Then, push the plunger upward to remove any possible air bubbles (figure 5B).
-
Pull the plunger down to the graduation mark on the oral syringe corresponding to the dose in milliliters (ml) prescribed by your doctor (figure 5C). The plunger may move back up inside the barrel during the first administration. Therefore, make sure the plunger remains in position until the syringe is disconnected from the bottle.
- Place the bottle upright (figure 6A). Remove the syringe from the adapter (figure 6B).
- Empty the contents of the syringe into a glass of water or into a feeding bottle by pushing the plunger down to the end of the syringe (figure 7).
|
|
| |
| |
|
Duration of treatment:
- Keppra is used as a chronic treatment. You must continue Keppra treatment for the duration indicated by your doctor.
- Do not stop your treatment without your doctor's recommendation, as your seizures may increase.
If you take more Keppra than you should
Possible adverse effects of an overdose of Keppra include somnolence, agitation, aggressiveness, decreased alertness, respiratory depression, and coma.
Contact your doctor if you have taken more oral solution than you should. Your doctor will determine the best treatment for the overdose.
If you forget to take Keppra:
Contact your doctor if you have missed one or more doses.
Do not take a double dose to make up for missed doses.
If you stop Keppra treatment:
Stopping Keppra treatment should be done gradually to avoid an increase in seizures. If your doctor decides to discontinue your Keppra treatment, they will provide instructions for the gradual withdrawal of Keppra.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible adverse effects
Like all medicines, Keppra can cause adverse effects, although not everyone will experience them.
Contact your doctor immediately, or go to the nearest hospital emergency department if you experience:
- weakness, dizziness, or difficulty breathing, as these may be signs of a severe allergic (anaphylactic) reaction;
- swelling of the face, lips, tongue, or throat (angioedema);
- flu-like symptoms and facial rash followed by a prolonged rash with high fever, elevated liver enzymes in blood tests, and an increase in a type of white blood cells (eosinophilia), enlarged lymph nodes, and involvement of other organs in the body (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS));
- symptoms such as low urine output, fatigue, nausea, vomiting, confusion, and swelling of legs, ankles, or feet, as these may be signs of sudden decrease in kidney function;
- a skin rash that may blister and may appear as small targets (dark centers surrounded by a paler area, with a dark ring around the edge) (erythema multiforme);
- a widespread rash with blisters and peeling of the skin, especially around the mouth, nose, eyes, and genitals (Stevens-Johnson syndrome);
- a more severe form causing skin peeling over more than 30% of the body surface (toxic epidermal necrolysis);
- signs of serious mental changes, or if someone around you notices signs of confusion, somnolence (drowsiness), amnesia (memory loss), memory impairment (forgetfulness), abnormal behavior, or other neurological signs including involuntary or uncontrolled movements. These may be symptoms of encephalopathy.
The most frequently reported adverse effects are nasopharyngitis, somnolence (drowsiness), headache, fatigue, and dizziness. Adverse effects such as drowsiness, feeling weak, and dizziness may be more common when treatment is started or when the dose is increased. However, these adverse effects should decrease over time.
Very common: may affect more than 1 in 10 people
- nasopharyngitis;
- somnolence (drowsiness), headache.
Common: may affect up to 1 in 10 people
- anorexia (loss of appetite);
- depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;
- seizures, balance disorder, dizziness (sensation of instability), lethargy (lack of energy and enthusiasm), tremor (involuntary shaking);
- vertigo (sensation of spinning);
- cough;
- abdominal pain, diarrhea, dyspepsia (indigestion, burning and acid regurgitation), vomiting, nausea;
- skin rash;
- asthenia/fatigue (feeling of weakness).
Uncommon: may affect up to 1 in 100 people
- decreased platelet count, decreased white blood cells;
- weight loss, weight gain;
- suicide attempt and suicidal thoughts, mental disturbances, abnormal behavior, hallucinations, anger, confusion, panic attack, emotional instability/mood changes, agitation;
- amnesia (memory loss), memory impairment (memory problems), abnormal coordination/ataxia (impaired movement coordination), paresthesia (tingling), attention disturbances (loss of concentration);
- diplopia (double vision), blurred vision;
- elevated/abnormal results in liver function tests;
- hair loss, eczema, itching;
- muscle weakness, myalgia (muscle pain);
- injury.
Rare: may affect up to 1 in 1,000 people
- infection;
- decrease in all types of blood cells;
- severe allergic reactions (DRESS, anaphylactic reaction (serious and severe allergic reaction), angioedema (swelling of face, lips, tongue, and throat));
- decreased concentration of sodium in the blood;
- suicide, personality disorders (behavioral problems), abnormal thinking (slow thinking, difficulty concentrating);
- delirium;
- encephalopathy (see subsection “Contact your doctor immediately” for a detailed description of symptoms);
- epileptic seizures may worsen or occur more frequently;
- uncontrollable muscle spasms affecting the head, trunk, and limbs, difficulty controlling movements, hyperkinesia (hyperactivity);
- change in heart rhythm (electrocardiogram);
- pancreatitis (inflammation of the pancreas);
- liver failure, hepatitis (inflammation of the liver);
- sudden decrease in kidney function;
- skin rash, which may lead to blisters appearing as small targets (dark centers surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling of the skin, especially around the mouth, nose, eyes, and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling over more than 30% of the body surface (toxic epidermal necrolysis);
- rhabdomyolysis (breakdown of muscle tissue) and associated increase in blood creatine phosphokinase. The prevalence is significantly higher in Japanese patients compared to non-Japanese patients;
- limping or difficulty walking;
- combination of fever, muscle rigidity, unstable blood pressure and heart rate, confusion, and decreased level of consciousness (may be signs of a disorder called neuroleptic malignant syndrome). The prevalence is significantly higher in Japanese patients compared to non-Japanese patients.
Very rare: may affect up to 1 in 10,000 people
- unwanted, repetitive thoughts or sensations, or the urge to do something over and over again (obsessive-compulsive disorder).
Reporting of adverse effects
If you experience any adverse effects, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You can also report them directly through the national reporting system listed in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Keppra Storage
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the bottle after EXP.
The expiry date refers to the last day of the month indicated.
Do not use more than 7 months after opening the container.
Store in the original bottle to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and containers that you no longer need. This will help protect the environment.
6. Contents of the pack and other information
Composition of Keppra
The active substance is levetiracetam. Each ml contains 100 mg of levetiracetam.
The other components are: sodium citrate, citric acid monohydrate, methyl 4-hydroxybenzoate (E218), propyl 4-hydroxybenzoate (E216), ammonium glycyrrhizinate, glycerol (E422), liquid maltitol (E965), potassium acesulfame (E950), grape flavour, purified water.
Appearance of the product and contents of the pack
Keppra 100 mg/ml oral solution is a clear liquid.
The 300 ml glass bottle of Keppra (for children from 4 years of age, adolescents and adults) is packaged in a cardboard box with a 10 ml oral syringe (graduated every 0.25 ml) and a syringe adapter.
The 150 ml glass bottle of Keppra (for infants and young children from 6 months up to less than 4 years of age) is packaged in a cardboard box with a 5 ml oral syringe (graduated every 0.1 ml from 0.3 ml to 5 ml and every 0.25 ml from 0.25 ml to 5 ml) and a syringe adapter.
The 150 ml glass bottle of Keppra (for infants from 1 month up to less than 6 months of age) is packaged in a cardboard box with a 1 ml oral syringe (graduated every 0.05 ml) and a syringe adapter.
Marketing Authorization Holder
UCB Pharma SA, Allée de la Recherche 60, B-1070 Brussels, Belgium.
Manufacturer
NextPharma SAS, 17 Route de Meulan, F-78520 Limay, France
or UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium
Further information on this medicinal product is available upon request by contacting the local representative of the Marketing Authorization Holder.
Belgium/Belgium/Belgium UCB Pharma SA/NV Tel/Tel: +32 / (0)2 559 92 00 | Lithuania UAB Medfiles Tel: +370 5 246 16 40 |
| Luxembourg/Luxembourg UCB Pharma SA/NV Tél/Tel: +32 / (0)2 559 92 00 (Belgium/Belgium) |
Czech Republic UCB s.r.o. Tel: +420 221 773 411 | Hungary UCB Magyarország Kft. Tel.: +36-(1) 391 0060 |
Denmark UCB Nordic A/S Tlf.: +45 / 32 46 24 00 | Malta Pharmasud Ltd. Tel: +356 / 21 37 64 36 |
Germany UCB Pharma GmbH Tel: +49 (0) 2173 48 4848 | Netherlands UCB Pharma B.V. Tel: +31 / (0)76-573 11 40 |
Estonia OÜ Medfiles Tel: +372 730 5415 | Norway UCB Nordic A/S Tlf: +47 / 67 16 5880 |
Greece UCB Α.Ε. Tel: +30 / 2109974000 | Austria UCB Pharma GmbH Tel: +43 (0)1 291 80 00 |
Spain UCB Pharma, S.A. Tel: +34 / 91 570 34 44 | Poland UCB Pharma Sp. z o.o. / VEDIM Sp. z o.o. Tel.: +48 22 696 99 20 |
France UCB Pharma Tél: +33 / (0)1 47 29 44 35 | Portugal UCB Pharma (Pharmaceutical Products), Lda. Tel: +351 / 21 302 5300 |
Croatia Medis Adria d.o.o. Tel: +385 (0) 1 230 34 46 | Romania UCB Pharma România S.R.L. Tel: +40 21 300 29 04 |
Ireland UCB (Pharma) Ireland Ltd. Tel: +353 / (0)1-46 37 395 | Slovenia Medis, d.o.o. Tel: +386 1 589 69 00 |
Iceland UCB Nordic A/S Sími: +45 / 32 46 24 00 | Slovakia UCB s.r.o., organizational unit Tel: +421 (0) 2 5920 2020 |
Italy UCB Pharma S.p.A. Tel: +39 / 02 300 791 | Finland UCB Pharma Oy Finland Puh/Tel: +358 9 2514 4221 |
Cyprus Lifepharma (Z.A.M.) Ltd Tel: +357 22 056300 | Sweden UCB Nordic A/S Tel: +46 / (0) 40 29 49 00 |
Latvia Medfiles SIA Tel: +371 67 370 250 |
Date of the most recent review of this leaflet:
Other sources of information
Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu.